Search
Displaying 621–630 of 1063 results
-
Beacon Stories
Tracy was the fourth generation of his family to receive the diagnosis of retinitis pigmentosa, but he never let that stop him from dreaming big. Tracy has worked at NASA’s Johnson Space Center for over 36 years, making significant contributions over the many years.
-
Disease
Refsum disease is an inherited condition that causes vision loss, absence of the sense of smell, and a number of other symptoms.
-
Release Date: June 5, 2020 Expiration Date: May 29, 2023
This activity offers CE credit for: a. Physicians (CME) b. Optometrists (COPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.
-
Virtual VISIONS 2020 Recorded Sessions
Recorded presentations from Virtual Visions 2020.
-
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Research NewsTreatment combines gene therapy and a device that generates and delivers retinal code
-
Foundation Fighting Blindness to Host Virtual VISIONS 2020 Conference
Foundation NewsThe national conference will be held virtually on June 25-27, providing the latest in science and research, practical adapting and thriving, and an opportunity to connect with others who are visually impaired.
-
Jumping into an Uncharted Arena
Beacon StoriesThirty-one-year-old Wren Blae Zimmerman always loved horses. But it wasn’t until a few years ago that Wren finally learned to ride. Now her life revolves around this equestrian dream, and she’s given herself the title of the “Blind Show Jumper.”
-
Research News
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Genentech’s Port Delivery System for Wet AMD Meets Primary Endpoint in Phase 3 Clinical Trial
Research NewsTiny implant provides continual delivery of anti-VEGF treatment for six months
-
Abfero Targeting Excess Iron to Treat AMD, Other Retinal Diseases
Partner NewsAn intriguing link between excess body iron and retinal degeneration is being explored by Abfero Pharmaceuticals, a young biotech based in Boston and Oxford, UK.
